Stem Cell-Derived Lactocytes for Sustainable Human Milk Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human milk are limited by the reliance on human donors, which is not sustainable or practical, and existing infant formula compositions fail to replicate the complexity of human milk due to missing components like lactoferrin, growth factors, and long-chain polyunsaturated fatty acids.
Innovation Solution
A method involving the culture and differentiation of mammalian induced pluripotent stem cells (miPSCs) using retinoic acid (RA) to generate mammary gland cells and lactocytes, which produce a mammalian milk-like product, including human milk, through the formation of mammary-like gland organoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human donors are used to produce human milk, then the milk contains all necessary bioactive components, but the method is not sustainable and has regulatory and safety constraints
Solution Approach 1:
The patent creates artificial mammary gland organoids that copy the structure and function of natural human mammary glands. These organoids are engineered to produce human milk with all its bioactive components (lactoferrin, growth factors, long-chain polyunsaturated fatty acids, oligosaccharides) without requiring human donors, thus resolving the contradiction between milk quality and production sustainability
Solution Approach 2:
The patent uses retinoic acid treatment to change the differentiation state of stem cells, inducing them to become functional lactocytes. This parameter change (chemical induction) enables sustainable production of high-quality human milk components while avoiding the limitations of donor-based methods
2Productivity
If current infant formula manufacturing processes are used, then production is scalable, but the formula fails to replicate human milk composition
Solution Approach 1:
The patent employs retinoic acid as a differentiating agent to transform stem cells into functional lactocytes that naturally produce the complex mixture of human milk components. This chemical parameter change enables the system to achieve both scalability (through cell culture expansion) and compositional accuracy (through biological synthesis of milk components)
Solution Approach 2:
The patent introduces an intermediary system - engineered mammary gland organoids - that acts as a biological factory. These organoids mediate between scalable cell culture processes and the production of authentic human milk components, resolving the contradiction between manufacturing scalability and compositional fidelity
Data Source
AI summary
A method for producing mammary gland cells and a method of producing a mammalian milk like product, for example a human milk like product comprising generating lactocytes derived from mammalian induced pluripotent stem cells (miPSC), for example human induced pluripotent stem cells (hiPSC), and expressing the mammalian milk like product, for example the human milk like product from lactocytes.